Karyopharm Therapeutics Inc (KPTI) Receives $16.83 Average Price Target from Analysts

Karyopharm Therapeutics Inc (NASDAQ:KPTI) has received a consensus recommendation of “Hold” from the ten ratings firms that are presently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $16.83.

Several equities research analysts have commented on the stock. BidaskClub cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 16th. ValuEngine cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, February 14th. Zacks Investment Research cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 2nd. Wedbush cut their price target on shares of Karyopharm Therapeutics from $19.00 to $14.00 and set an “outperform” rating on the stock in a research report on Monday, February 25th. Finally, HC Wainwright reissued a “buy” rating on shares of Karyopharm Therapeutics in a research report on Wednesday, February 27th.

In other news, major shareholder Ltd Chione sold 800,000 shares of the business’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $4.99, for a total transaction of $3,992,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 13.26% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc grew its stake in Karyopharm Therapeutics by 31.3% in the 4th quarter. Legal & General Group Plc now owns 10,116 shares of the company’s stock valued at $95,000 after buying an additional 2,411 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in Karyopharm Therapeutics by 660.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,800 shares of the company’s stock valued at $36,000 after buying an additional 3,300 shares during the last quarter. DekaBank Deutsche Girozentrale grew its stake in Karyopharm Therapeutics by 20.7% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 19,800 shares of the company’s stock valued at $419,000 after buying an additional 3,400 shares during the last quarter. IFP Advisors Inc grew its stake in Karyopharm Therapeutics by 197.4% in the 4th quarter. IFP Advisors Inc now owns 5,650 shares of the company’s stock valued at $52,000 after buying an additional 3,750 shares during the last quarter. Finally, Knott David M grew its stake in Karyopharm Therapeutics by 12.5% in the 4th quarter. Knott David M now owns 36,000 shares of the company’s stock valued at $337,000 after buying an additional 4,000 shares during the last quarter. Institutional investors own 86.46% of the company’s stock.

NASDAQ:KPTI traded down $0.10 on Friday, hitting $4.69. 742,300 shares of the company’s stock were exchanged, compared to its average volume of 1,336,721. The company has a debt-to-equity ratio of 0.98, a current ratio of 6.19 and a quick ratio of 6.19. Karyopharm Therapeutics has a 52 week low of $3.92 and a 52 week high of $21.71. The stock has a market capitalization of $282.39 million, a PE ratio of -1.49 and a beta of 3.09.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.25). Karyopharm Therapeutics had a negative return on equity of 119.66% and a negative net margin of 1,005.85%. The business had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.75 million. On average, analysts anticipate that Karyopharm Therapeutics will post -3.69 earnings per share for the current fiscal year.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.

See Also: Price to Earnings Ratio (PE), For Valuing Stocks

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.